Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00061867 | Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer | PHASE1 | COMPLETED | - | — | — | Mar 1, 2003 | Aug 1, 2005 | May 30, 2013 | 2 | United States |
| Name | Type | Description |
|---|---|---|
| pegylated liposomal doxorubicin hydrochloride | DRUG | - |
| hyperthermia treatment | PROCEDURE | - |
DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the prostate * Rising prostate-specific antigen AND radiographic evidence of extraprostatic prostate cancer by bone scan, CT scan, prostascint scan, or MRI PATIENT CHARACTERISTICS: Age * 40 and over Performance status * Karn...